[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism-acute-massive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism-acute-massive":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,69,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100567737","early-catheter-directed-treatment-of-high-risk-pulmonary-embolism-100567737",false,"NCT06672081","Early Catheter-directed Treatment of High Risk Pulmonary Embolism","A Randomized Trial for Early Catheter-directed Treatment of High Risk Pulmonary Embolism","CATCH-PE II","Inclusion Criteria:\n\n1. Pulmonary embolism as confirmed by CT angiogram with high mortality risk as defined by ESC guidelines:\n\n   a) One of the following: i. Cardiac arrest or ii. obstructive shock (systolic BP \\\u003C90 mmHg or vasopressors required to achieve a BP ≥90 mmHg despite an adequate filling status), in combination with end-organ hypoperfusion (cold, clammy skin, oliguria or serum lactate ≥2 mmol\u002FL) and b) Signs of right-ventricular dysfunction on transthoracic echocardiogram or CT scan\n2. Age ≥18 years\n\nExclusion Criteria:\n\n1. Contraindications for catheter-based treatment\n2. Contraindications to systemic fibrinolytic treatment or anticoagulation\\*\n\n   1. Active, potentially life-threatening bleeding\n   2. Surgery within 24h before screening\n   3. Cranial or spinal surgery within 14d before screening\n   4. Stroke within 14d before screening\n   5. Intracranial tumor\n   6. Any condition not listed here but estimated as clinically relevant as judged by the treating investigator\n3. Pregnancy\n\n   * Patients with contraindications to systemic fibrinolysis or anticoagulation can be enrolled in a third study arm (registry) and undergo catheter-directed therapy.","ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"NA","Prospective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism",[27],"Pulmonary Embolism Acute Massive",[29,30],"pulmonary embolism","early catheter-directed treatment","RECRUITING","2026-03-03",{"date":34,"type":35},"2026-03-04","ACTUAL",{"date":37,"type":35},"2024-12-27",{"date":39,"type":21},"2027-06-30",{"name":41,"class":42},"Leipzig Heart Science gGmbH","OTHER",18,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100611849","post-registration-trial-of-the-non-immunogenic-staphylokinase-in-massive-pulmonary-embolism-100611849","NCT07245927","Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism","An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Massive Pulmonary Embolism (FORPE Registry)","Inclusion Criteria:\n\n* Men and women aged 18 years and older.\n* Verified diagnosis of massive pulmonary embolism (using computer tomography)\n* Signs of overload \u002F dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock\n* The time from the symptoms onset is no more than 14 days.\n* Thrombolysis with the non-immunogenic staphylokinase, 15 mg as a single intravenous bolus.\n\nExclusion Criteria:\n\n* Increased risk of bleeding:\n\n  * extensive bleeding at present or within the previous 6 months;\n  * intracranial (including subarachnoid) hemorrhage at present or in history;\n  * hemorrhagic stroke within the last 6 months;\n  * a history of diseases of the central nervous system (including neoplasms, aneurysms);\n  * intracranial or spinal surgical interventions within the last 2 months;\n  * major surgery or major trauma within the previous 4 weeks;\n  * recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein);\n  * severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis;\n  * confirmed gastric or duodenal ulcer within the last 3 months;\n  * neoplasm with an increased risk of bleeding;\n  * simultaneous administration of Dabigatran without prior administration of idarucizumab;\n  * arterial aneurysms, developmental defects of arteries \u002F veins;\n  * acute pancreatitis;\n  * bacterial endocarditis, pericarditis;\n  * suspicion of aortic dissecting aneurysm;\n  * any other conditions, in the opinion of the investigator, associated with a high risk of bleeding.\n* Lactation, pregnancy.\n* Known hypersensitivity to the non-immunogenic recombinant staphylokinase.",{"count":52,"type":21},20000,"OBSERVATIONAL","The aim of FORPE Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with massive pulmonary embolism in routine clinical practice.",[27],[57],"Pulmonary Embolism","2025-11-17",{"date":60,"type":35},"2025-11-24",{"date":62,"type":35},"2025-06-01",{"date":64,"type":21},"2027-12-31",{"name":66,"class":67},"Supergene, LLC","INDUSTRY",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":53,"phases":4,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":68},"100595237","cohort-study-on-treatment-comes-of-catheter-based-therapy-in-patients-with-acute-pulmonary-embolism-in-hong-kong-100595237","NCT07029841","Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong","Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong - the HONG KONG PECT Registry","HK-PECT","Inclusion Criteria:\n\n* Patients who is admitted with a diagnosis of acute pulmonary embolism\n* Patient who receives any types of catheter-based therapy for acute pulmonary embolism.\n\nExclusion Criteria:\n\n* nil. This is a all-comer registry.",{"count":78,"type":21},1000,"90 Days","This retrospective cohort study (Hong Kong PECT Registry) compares treatment outcomes between different percutaneous catheter-based therapies in patients with acute pulmonary embolism (PE). PE is a critical condition with potential for rapid deterioration and mortality before treatment. While availability of catheter-based therapy contributed to the declining mortality rates of PE, selecting the appropriate intervention remains key. There are primarily two modes of therapies available: Catheter-directed thrombolysis and Aspiration thrombectomy (e.g., Penumbra, Flowtriever, AlphaVac) Given limited direct comparisons between these methods, the study will evaluate their efficacy, safety, and clinical outcomes of these treatment strategies in acute PE patients.",[82,27,83],"Pulmonary Embolism Acute","Pulmonary Embolism Subacute Massive",[85],"PE, CDT, LBAT, UACDT","2025-06-17",{"date":88,"type":35},"2025-06-19",{"date":90,"type":35},"2022-06-01",{"date":92,"type":21},"2032-12-30",{"name":94,"class":42},"Chinese University of Hong Kong",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":104,"studyType":53,"phases":4,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":68},"100542868","registry-of-catheter-intervention-in-pulmonary-embolism-100542868","NCT06348459","Registry of Catheter Intervention in Pulmonary Embolism","RiTEP","Inclusion Criteria:\n\n* adult patients (aged 18 years old or older)\n* confirmed diagnosis of acute PE (on computed tomography or echocardiogram plus pulmonary angiography)\n* high-risk PE or intermediate-high risk according to ESC risk stratification in the 2019 guidelines (briefly, elevated cardiac biomarkers \\[troponin or N-terminal pro-B-type natriuretic peptide\\], and right ventricle to left ventricle ratio \\> 0.9 \\[on computed tomography or echocardiogram\\], and PE severity index III to IV or simplified PE severity index=1\n* eligibility for catheter-directed intervention\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of PE\n* undefined risk stratification, and\n* PE with uncertain chronology or beyond seven days of symptom initiation.",{"count":103,"type":21},300,"2 Years","Multicenter longitudinal observational ambispective (retrospective cases from 2014 and prospective from 2018 onwards) cohort study. The registry recruits a series of consecutive patients admitted for moderate-high risk or high-risk pulmonary embolism (according to 2019 European Society of Cardiology guidelines) treated invasively. This study aims to describe the acute management of the safety and effectiveness of different percutaneous interventions for acute pulmonary embolism.",[57,27,82,107,108],"Pulmonary Embolism and Thrombosis","Pulmonary Thromboembolisms",[110,111,112],"Aspiration Thrombectomy","Percutaneous Aspiration Thrombectomy","Local Thrombolysis","2025-04-23",{"date":115,"type":35},"2025-04-25",{"date":117,"type":35},"2018-09-18",{"date":119,"type":21},"2030-12-31",{"name":121,"class":42},"Hospital San Carlos, Madrid"]